Roswell Park Comprehensive Cancer Center and Generate:Biomedicines announce a strategic collaboration to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors. In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.